Negative predictive value of pap testing: Implications for screening intervals for women with human immunodeficiency virus

L. Stewart Massad, Gypsyamber D'Souza, Fang Tian, Howard Minkoff, Mardge Cohen, Rodney L. Wright, Christine Colie, Nancy A. Hessol

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

OBJECTIVE: To estimate the accuracy of Pap testing for women who are human immunodeficiency virus (HIV)-seropositive, with a focus on negative predictive value. METHODS: Participants in the Women's Interagency HIV Study were monitored with conventional Pap tests every 6 months. After excluding those with abnormal Pap test results before study, cervical disease, or hysterectomy, women with negative enrollment Pap test results were monitored for development of precancer within 15 or 39 months, defined as a Pap test result read as high-grade squamous intraepithelial lesion, atypical glandular cells favor neoplasia, or adenocarcinoma in situ, or a cervical biopsy read as cervical intraepithelial neoplasia 2 or worse. Correlations between one or more consecutive negative Pap test results and subsequent precancer were assessed using Cox proportional hazards models. RESULTS: Among 942 HIV-infected women with negative baseline Pap test results, eight (1%) developed precancer within 15 months and 40 (4%) within 39 months. After three consecutive negative Pap test results, precancer was rare, with no cases within 15 months and 10 of 539 (2%) within 39 months. No women developed precancer or cancer within 39 months after 10 consecutive negative Pap test results. Risks for precancer within 15 months after negative Pap test result included current smoking (adjusted hazard ratio [HR] 1.5, 95% confidence interval [CI] 1.2-2.0 compared with nonsmokers), younger age (adjusted HR 1.5, 95% CI 1.1-2.1 for women aged younger than 31 years compared with older than 45 years), and lower CD4 count (adjusted HR 11.8, 95% CI 1.3-2.3 for CD4 200-500/microliter, adjusted HR 2.2, 95% CI 1.6-2.9 for CD4 less than 200/microliter, compared with CD4 more than 500/microliter). CONCLUSION: Annual Pap testing appears safe for women infected with HIV; for those with serial negative tests, longer intervals are appropriate.

Original languageEnglish (US)
Pages (from-to)791-797
Number of pages7
JournalObstetrics and Gynecology
Volume120
Issue number4
DOIs
StatePublished - Oct 2012
Externally publishedYes

Fingerprint

Papanicolaou Test
HIV
Confidence Intervals
Cervical Intraepithelial Neoplasia
CD4 Lymphocyte Count
Hysterectomy
Proportional Hazards Models
Neoplasms
Smoking
Biopsy

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Negative predictive value of pap testing : Implications for screening intervals for women with human immunodeficiency virus. / Massad, L. Stewart; D'Souza, Gypsyamber; Tian, Fang; Minkoff, Howard; Cohen, Mardge; Wright, Rodney L.; Colie, Christine; Hessol, Nancy A.

In: Obstetrics and Gynecology, Vol. 120, No. 4, 10.2012, p. 791-797.

Research output: Contribution to journalArticle

Massad, L. Stewart ; D'Souza, Gypsyamber ; Tian, Fang ; Minkoff, Howard ; Cohen, Mardge ; Wright, Rodney L. ; Colie, Christine ; Hessol, Nancy A. / Negative predictive value of pap testing : Implications for screening intervals for women with human immunodeficiency virus. In: Obstetrics and Gynecology. 2012 ; Vol. 120, No. 4. pp. 791-797.
@article{480d2cc1c35d4fd5bda674fdc64e570b,
title = "Negative predictive value of pap testing: Implications for screening intervals for women with human immunodeficiency virus",
abstract = "OBJECTIVE: To estimate the accuracy of Pap testing for women who are human immunodeficiency virus (HIV)-seropositive, with a focus on negative predictive value. METHODS: Participants in the Women's Interagency HIV Study were monitored with conventional Pap tests every 6 months. After excluding those with abnormal Pap test results before study, cervical disease, or hysterectomy, women with negative enrollment Pap test results were monitored for development of precancer within 15 or 39 months, defined as a Pap test result read as high-grade squamous intraepithelial lesion, atypical glandular cells favor neoplasia, or adenocarcinoma in situ, or a cervical biopsy read as cervical intraepithelial neoplasia 2 or worse. Correlations between one or more consecutive negative Pap test results and subsequent precancer were assessed using Cox proportional hazards models. RESULTS: Among 942 HIV-infected women with negative baseline Pap test results, eight (1{\%}) developed precancer within 15 months and 40 (4{\%}) within 39 months. After three consecutive negative Pap test results, precancer was rare, with no cases within 15 months and 10 of 539 (2{\%}) within 39 months. No women developed precancer or cancer within 39 months after 10 consecutive negative Pap test results. Risks for precancer within 15 months after negative Pap test result included current smoking (adjusted hazard ratio [HR] 1.5, 95{\%} confidence interval [CI] 1.2-2.0 compared with nonsmokers), younger age (adjusted HR 1.5, 95{\%} CI 1.1-2.1 for women aged younger than 31 years compared with older than 45 years), and lower CD4 count (adjusted HR 11.8, 95{\%} CI 1.3-2.3 for CD4 200-500/microliter, adjusted HR 2.2, 95{\%} CI 1.6-2.9 for CD4 less than 200/microliter, compared with CD4 more than 500/microliter). CONCLUSION: Annual Pap testing appears safe for women infected with HIV; for those with serial negative tests, longer intervals are appropriate.",
author = "Massad, {L. Stewart} and Gypsyamber D'Souza and Fang Tian and Howard Minkoff and Mardge Cohen and Wright, {Rodney L.} and Christine Colie and Hessol, {Nancy A.}",
year = "2012",
month = "10",
doi = "10.1097/AOG.0b013e31826a8bbd",
language = "English (US)",
volume = "120",
pages = "791--797",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Negative predictive value of pap testing

T2 - Implications for screening intervals for women with human immunodeficiency virus

AU - Massad, L. Stewart

AU - D'Souza, Gypsyamber

AU - Tian, Fang

AU - Minkoff, Howard

AU - Cohen, Mardge

AU - Wright, Rodney L.

AU - Colie, Christine

AU - Hessol, Nancy A.

PY - 2012/10

Y1 - 2012/10

N2 - OBJECTIVE: To estimate the accuracy of Pap testing for women who are human immunodeficiency virus (HIV)-seropositive, with a focus on negative predictive value. METHODS: Participants in the Women's Interagency HIV Study were monitored with conventional Pap tests every 6 months. After excluding those with abnormal Pap test results before study, cervical disease, or hysterectomy, women with negative enrollment Pap test results were monitored for development of precancer within 15 or 39 months, defined as a Pap test result read as high-grade squamous intraepithelial lesion, atypical glandular cells favor neoplasia, or adenocarcinoma in situ, or a cervical biopsy read as cervical intraepithelial neoplasia 2 or worse. Correlations between one or more consecutive negative Pap test results and subsequent precancer were assessed using Cox proportional hazards models. RESULTS: Among 942 HIV-infected women with negative baseline Pap test results, eight (1%) developed precancer within 15 months and 40 (4%) within 39 months. After three consecutive negative Pap test results, precancer was rare, with no cases within 15 months and 10 of 539 (2%) within 39 months. No women developed precancer or cancer within 39 months after 10 consecutive negative Pap test results. Risks for precancer within 15 months after negative Pap test result included current smoking (adjusted hazard ratio [HR] 1.5, 95% confidence interval [CI] 1.2-2.0 compared with nonsmokers), younger age (adjusted HR 1.5, 95% CI 1.1-2.1 for women aged younger than 31 years compared with older than 45 years), and lower CD4 count (adjusted HR 11.8, 95% CI 1.3-2.3 for CD4 200-500/microliter, adjusted HR 2.2, 95% CI 1.6-2.9 for CD4 less than 200/microliter, compared with CD4 more than 500/microliter). CONCLUSION: Annual Pap testing appears safe for women infected with HIV; for those with serial negative tests, longer intervals are appropriate.

AB - OBJECTIVE: To estimate the accuracy of Pap testing for women who are human immunodeficiency virus (HIV)-seropositive, with a focus on negative predictive value. METHODS: Participants in the Women's Interagency HIV Study were monitored with conventional Pap tests every 6 months. After excluding those with abnormal Pap test results before study, cervical disease, or hysterectomy, women with negative enrollment Pap test results were monitored for development of precancer within 15 or 39 months, defined as a Pap test result read as high-grade squamous intraepithelial lesion, atypical glandular cells favor neoplasia, or adenocarcinoma in situ, or a cervical biopsy read as cervical intraepithelial neoplasia 2 or worse. Correlations between one or more consecutive negative Pap test results and subsequent precancer were assessed using Cox proportional hazards models. RESULTS: Among 942 HIV-infected women with negative baseline Pap test results, eight (1%) developed precancer within 15 months and 40 (4%) within 39 months. After three consecutive negative Pap test results, precancer was rare, with no cases within 15 months and 10 of 539 (2%) within 39 months. No women developed precancer or cancer within 39 months after 10 consecutive negative Pap test results. Risks for precancer within 15 months after negative Pap test result included current smoking (adjusted hazard ratio [HR] 1.5, 95% confidence interval [CI] 1.2-2.0 compared with nonsmokers), younger age (adjusted HR 1.5, 95% CI 1.1-2.1 for women aged younger than 31 years compared with older than 45 years), and lower CD4 count (adjusted HR 11.8, 95% CI 1.3-2.3 for CD4 200-500/microliter, adjusted HR 2.2, 95% CI 1.6-2.9 for CD4 less than 200/microliter, compared with CD4 more than 500/microliter). CONCLUSION: Annual Pap testing appears safe for women infected with HIV; for those with serial negative tests, longer intervals are appropriate.

UR - http://www.scopus.com/inward/record.url?scp=84866934686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866934686&partnerID=8YFLogxK

U2 - 10.1097/AOG.0b013e31826a8bbd

DO - 10.1097/AOG.0b013e31826a8bbd

M3 - Article

C2 - 22996096

AN - SCOPUS:84866934686

VL - 120

SP - 791

EP - 797

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 4

ER -